The B7-H1 (PD-L1)T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors1
| Autor: | Ghebeh, Hazem, Mohammed, Shamayel, Al-Omair, Abeer, Qattan, Amal, Lehe, Cynthia, Al-Qudaihi, Ghofran, Elkum, Naser, Alshabanah, Mohamed, Amer, Suad Bin, Tulbah, Asma, Ajarim, Dahish, Al-Tweigeri, Taher, Dermime, Said |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
Adult
Neoplasms Hormone-Dependent Saudi Arabia Breast Neoplasms B7-H1 Antigen Lymphocytes Tumor-Infiltrating Antigens CD Risk Factors Cell Line Tumor Humans Mastectomy Progesterone Aged Carcinoma Ductal Breast Epithelial Cells Estrogens Middle Aged Prognosis Combined Modality Therapy Neoadjuvant Therapy Neoplasm Proteins Tumor Burden Receptors Estrogen Lymphatic Metastasis Female Tumor Escape Receptors Progesterone Research Article |
| Popis: | B7-H1 molecule increases the apoptosis of tumor-reactive T lymphocytes and reduces their immunogenicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|